



Improving access.
Transforming health.

July 10, 2025

The Honorable Glenn Grothman
1211 Longworth HOB
Washington, DC 20510

The Honorable Suzanne Bonamici
2231 Rayburn HOB
Washington, DC 20510

Dear Representative Grothman and Bonamici,

On behalf of the Patient Access Network (PAN) Foundation and the patients and families we assist, I write in support of the *Cancer Drug Parity Act of 2025* (H.R. 4101). PAN commends you for reintroducing this critical legislation that will expand access to breakthrough treatments for those battling cancer.

As a leading charitable foundation and healthcare advocacy organization, the PAN Foundation is dedicated to accelerating access to treatment for those who need it most and empowering patients on their healthcare journeys. We provide critical financial assistance for treatment costs, advocate for policy solutions that expand access to care, and deliver education on complex topics—all driven by our belief that everyone deserves access to affordable, equitable healthcare.

Prescription oral chemotherapies are becoming increasingly common, with nearly 40% of all anticancer drugs in the oncology development pipeline expected to be in pill form. These treatments offer patients a transformative option to receive care and recover in the comfort of their own homes. However, despite clear clinical benefits and advances in cancer treatment, outdated insurance policies still prevent many patients from accessing their prescribed—and sometimes only—treatment option. Estimates show that oral cancer drugs can cost Medicare beneficiaries more than \$11,000 a year, creating an unfair and often insurmountable barrier to care. While 43 states and the District of Columbia have enacted oral parity legislation, many Americans still lack these protections. The *Cancer Drug Parity Act of 2025* will help ensure that *every* person fighting cancer can make treatment decisions based on what's best for their health and reduce financial strain that has for too long limited or denied access to life-saving care.

The PAN Foundation appreciates your leadership in seeking solutions to increase access to and affordability of health care for more Americans. We look forward to working with you to educate on the importance of passing the *Cancer Drug Parity Act of 2025*. If you would like further information or have questions, please contact Amy Niles, Chief Mission Officer at aniles@panfoundation.org.

Sincerely,

A handwritten signature in black ink that reads "Kevin L. Hagan". The signature is fluid and cursive, with the first name "Kevin" being the most prominent part.

Kevin L. Hagan
President and Chief Executive Officer

cc: The Honorable Gus Bilirakis
The Honorable Brian Fitzpatrick
The Honorable Joe Morelle
The Honorable Doris Matsui